Transient Increased Risk of Shingles Post-Shingrix Vaccination: Self-Controlled Case-Series Analysis.

ABSTRACT:

Background

Following the introduction of a funded recombinant shingles vaccine (RZV; Shingrix, GlaxoSmithKline) vaccination program in adults aged ≥65 years in Australia, clinician reports of shingles presentations shortly after vaccination emerged. We investigated whether there was an increase in shingles risk immediately post-RZV vaccination in southeastern Australia.

Methods

Two independent datasets-a general practice dataset and a statewide linked dataset-were analyzed separately using self-controlled case series (SCCS) analyses with 21 days postvaccination as the risk window. The observation period was 1 January 2023 to 30 April 2025. Adults ≥18 years were included, with analyses stratified by age (<65 and ≥65 years) and sex. We calculated the rate of incident shingles

SUBMITTER: Shetty AN 

PROVIDER: S-EPMC12728290 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature